Results: 35

Progression of Relapsing-Remitting Multiple Sclerosis despite the new era of treatments

Objective. The present study aims to evaluate the conditions associated with the progression of Multiple Sclerosis (MS) and patients’ dysfunctions. Methods. We perform aretrospective longitudinal analytical observational study in 46 patients with MS from a polyclinic in Rio de Janeiro, Brazil. We used ...

Serum levels of irisin and nesfatin-1 in multiple sclerosis

Arq. neuropsiquiatr; 80 (2), 2022
ABSTRACT Background: Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune chronic neurological disease. Currently, there are no effective serum biomarkers to verify MS diagnosis, to assess disease prognosis, and evaluate response to MS treatment. Objective: The present study is...

Estudio exploratorio para la validación de la Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) en la población con esclerosis múltiple remitente recurrente del Hospital San Juan de Dios en Santiago de Chile

La evaluación cognitiva en personas adultas con esclerosis múltiple (EM) es un área fundamental a tener en cuenta en el proceso de intervención, debido a la alta prevalencia de deterioro cognitivo. En la actualidad, se ha recomendado la evaluación cognitiva por medio de la BICAMS (del inglés Brief ...

Esclerosis múltiple remitente-recurrente en el contexto de la salud pública de Villa Clara
Relapsing-Remitting Multiple Sclerosis in the context of public health in Villa Clara

Edumecentro; 14 (), 2022
RESUMEN Fundamento: no se dispone de una información científica con representatividad nacional sobre la esclerosis múltiple, aspecto importante no solo para el control epidemiológico, sino también para la superación actualizada en términos de educación médica y en relación con proyectos geren...

Valor pronóstico del glutamato en el líquido cefalorraquídeo en esclerosis múltiple

Medicina (B.Aires); 81 (5), 2021
Resumen El objetivo del trabajo fue evaluar la asociación entre el nivel de glutamato en el líquido cefalorraquídeo (LCR) al inicio de la enfermedad y la progresión de la enfermedad durante el seguimiento en una cohorte de pacientes con esclerosis múltiple (EM). Se determinaron niveles de glutamato ...

Motor symptoms and the quality of life of relapsing-remitting multiple sclerosis patients in a specialized center in South of Brazil

Arq. neuropsiquiatr; 79 (10), 2021
Abstract Background: Spasticity, fatigue, muscle weakness and changes in gait are some of the main motor symptoms of Multiple Sclerosis (MS). These changes can interfere with the patients' quality of life. Objective: To characterize the motor and quality of life symptoms in patients with relapsing-remi...

Serum YKL-40 levels in patients with multiple sclerosis

Arq. neuropsiquiatr; 79 (9), 2021
ABSTRACT Background: Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system. The YKL-40 protein, which is secreted from various cells that contribute to inflammation and infection, plays a role in immune regulation. Objective: This study investigated the serum YK...

Regional brain atrophy is related to social cognition impairment in multiple sclerosis

Arq. neuropsiquiatr; 79 (8), 2021
ABSTRACT Background: Multiple sclerosis exhibits specific neuropathological phenomena driving to both global and regional brain atrophy. At the clinical level, the disease is related to functional decline in cognitive domains as the working memory, processing speed, and verbal fluency. However, the comp...

Determinants of disability development in patients with multiple sclerosis

Arq. neuropsiquiatr; 79 (6), 2021
Abstract Background: Multiple sclerosis (MS) is one of the most common chronic neurological diseases affecting the central nervous system in young adults. Objective: To investigate demographic and clinical factors that are effective in the development of irreversible disability from the onset of MS, an...

Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile

Arq. neuropsiquiatr; 79 (5), 2021
ABSTRACT Background: The real-world effectiveness of natalizumab in people with relapsing multiple sclerosis (PwRMS) in Argentina and Chile has not been reported. Objective: To evaluate the effectiveness of natalizumab treatment in PwRMS in Argentina and Chile, in clinical practice. Methods: We conduc...